Terumo, India

Terumo India Advances Treatment Options for Heart Disease with the Launch of Ultimaster Nagomi

18.12.2023 - 08:30:28

Business Wire India
Terumo India, the Indian arm of Japan based Terumo Corporation (TSE: 4543), a global leader in medical technology, recently announced the launch of Ultimaster Nagomi™, a Drug-Eluting Stent intended for use in the treatment of coronary artery disease.

Cardiovascular disease is the cause of 25% of all deaths in India with a prevalence of around 54.5 million in the country.

Drug-Eluting Stents (DES) are specialized types of stents meant for use in the treatment of coronary artery disease. Investments are being made towards newer generation stents which can enhance the safety and effectiveness of coronary artery treatments.

Ultimaster Nagomi™, by Terumo India, is one such new generation Drug-Eluting Stent that can facilitate smooth navigation to complex arteries and adapt to any vessel size with ease. The optimal design of the Ultimaster Nagomi™ makes it suitable for any small or large sized coronary artery, enabling customized stent selection for a larger patient subset.

Mr. Shishir Agarwal, President and Managing Director of Terumo India, expressed, "Ultimaster Nagomi™? embodies the legacy of Japanese technology, supported by robust clinical evidence from the Ultimaster™? family across various procedures. Our goal is to introduce cutting-edge Japanese technologies to benefit all Indian patients, allowing them access to the latest innovations in healthcare."

Elaborating on the need, (https://terumoindia.com/)

Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo’s starting point and unchanging corporate mission has been ‘Contributing to Society through Healthcare’.

Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognized as one of India’s Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India’s healthcare system.
 
About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
@ businesswireindia.com